Compare AstraZeneca plc (AZN) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Zeta Global Holdings Corp — how do they compare? AstraZeneca plc trades at $168.69 (market cap $253.13B), while Zeta Global Holdings Corp trades at $22.4 (market cap $5.62B). The key difference: AstraZeneca plc is far larger — about 45× Zeta Global Holdings Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| AZN | ZETA | |
|---|---|---|
Market Cap | $253.13B | $5.62B |
Sector | Health | Technology |
52-Week High | $209.48 | $25.24 |
52-Week Low | $137.44 | $14.04 |
Enterprise Value | $279.37B | $5.52B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
ZETA trades at $21.87, up 1.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats and accelerating revenue growth, reaching $1.3B in 2025. Recent AI partnerships with Palantir and OpenAI signal strategic transformation, though negative net margins and cash flow challenges persist. Technical indicators show bullish moving averages with RSI approaching overbought territory near 70.
ZETA presents growth potential through AI platform expansion but faces profitability challenges. The 27% upside to consensus price target of $27.50 offers opportunity, while negative margins and cash flow require monitoring. Investment thesis hinges on successful AI monetization versus ongoing margin pressure from agency-led channels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
